Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy
Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods. Baseline neutrophil-to-lymphocyte ratio, lacta...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2023-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/2529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849252208640524288 |
|---|---|
| author | D. I. Yudin K. K. Laktionov K. A. Sarantseva T. D. Barbolina I. A. Djanyan |
| author_facet | D. I. Yudin K. K. Laktionov K. A. Sarantseva T. D. Barbolina I. A. Djanyan |
| author_sort | D. I. Yudin |
| collection | DOAJ |
| description | Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods. Baseline neutrophil-to-lymphocyte ratio, lactate dehydrogenase, hemoglobin, platelets, and fibrinogen level were collected from 133 patients treated with ICI in monotherapy or combination between July 2015 and July 2022 in N.N. Blokhin NMRCO. According to evaluating factors patients were divided into three groups of “good” (LIPI 0/mLIPI 0–1), “intermediate” (LIPI 1/mLIPI 2–3) and “poor” prognosis (LIPI 2/mLIPI 4–5). The primary endpoint was progression free survival (PFS).Results. The median PFS for the LIPI groups were 9.7 months (1.4–17.9; 95 % CI), 7.9 months (5.9–9.9; CI 95 %) and 6.0 months (4.07–7.93; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively; the hazard ratio (HR) for patients in the “poor” prognosis group (17 patients) was 2.02 (1.06–3.84; 95 % CI) compared with the “good” LIPI group (p=0.03). The median PFS for mLIPI groups were 9.0 months (4.53–13.47; 95 % CI), 8.0 months (5.4–10.6; CI 95 %) and 2.0 months. (1.33–2.67; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively. The HR for patients in the “poor” prognosis group (n=12) was 3.12 (1.51–6.46; 95 % CI) compared with the “good” mLIPI group (p=0.002).Conclusion. Baseline LIPI and mLIPI predicts potential resistance to ICI treatment in mNSCLC patients. |
| format | Article |
| id | doaj-art-711ddfebc8424d3c82687bb8d30323b2 |
| institution | Kabale University |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2023-05-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-711ddfebc8424d3c82687bb8d30323b22025-08-20T03:56:41ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682023-05-01222566410.21294/1814-4861-2023-22-2-56-641104Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapyD. I. Yudin0K. K. Laktionov1K. A. Sarantseva2T. D. Barbolina3I. A. Djanyan4N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the RussiaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia; N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the RussiaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the RussiaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia; A.I. Evdokimov Moscow State Medical UniversityN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the RussiaAim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods. Baseline neutrophil-to-lymphocyte ratio, lactate dehydrogenase, hemoglobin, platelets, and fibrinogen level were collected from 133 patients treated with ICI in monotherapy or combination between July 2015 and July 2022 in N.N. Blokhin NMRCO. According to evaluating factors patients were divided into three groups of “good” (LIPI 0/mLIPI 0–1), “intermediate” (LIPI 1/mLIPI 2–3) and “poor” prognosis (LIPI 2/mLIPI 4–5). The primary endpoint was progression free survival (PFS).Results. The median PFS for the LIPI groups were 9.7 months (1.4–17.9; 95 % CI), 7.9 months (5.9–9.9; CI 95 %) and 6.0 months (4.07–7.93; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively; the hazard ratio (HR) for patients in the “poor” prognosis group (17 patients) was 2.02 (1.06–3.84; 95 % CI) compared with the “good” LIPI group (p=0.03). The median PFS for mLIPI groups were 9.0 months (4.53–13.47; 95 % CI), 8.0 months (5.4–10.6; CI 95 %) and 2.0 months. (1.33–2.67; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively. The HR for patients in the “poor” prognosis group (n=12) was 3.12 (1.51–6.46; 95 % CI) compared with the “good” mLIPI group (p=0.002).Conclusion. Baseline LIPI and mLIPI predicts potential resistance to ICI treatment in mNSCLC patients.https://www.siboncoj.ru/jour/article/view/2529nsclcprognostic factorsimmunotherapylung immune prognostic index lipi. |
| spellingShingle | D. I. Yudin K. K. Laktionov K. A. Sarantseva T. D. Barbolina I. A. Djanyan Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy Сибирский онкологический журнал nsclc prognostic factors immunotherapy lung immune prognostic index lipi. |
| title | Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy |
| title_full | Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy |
| title_fullStr | Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy |
| title_full_unstemmed | Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy |
| title_short | Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy |
| title_sort | evaluation and modifcation of lung immune prognostic index in patients with metastatic nsclc treated by immunotherapy |
| topic | nsclc prognostic factors immunotherapy lung immune prognostic index lipi. |
| url | https://www.siboncoj.ru/jour/article/view/2529 |
| work_keys_str_mv | AT diyudin evaluationandmodifcationoflungimmuneprognosticindexinpatientswithmetastaticnsclctreatedbyimmunotherapy AT kklaktionov evaluationandmodifcationoflungimmuneprognosticindexinpatientswithmetastaticnsclctreatedbyimmunotherapy AT kasarantseva evaluationandmodifcationoflungimmuneprognosticindexinpatientswithmetastaticnsclctreatedbyimmunotherapy AT tdbarbolina evaluationandmodifcationoflungimmuneprognosticindexinpatientswithmetastaticnsclctreatedbyimmunotherapy AT iadjanyan evaluationandmodifcationoflungimmuneprognosticindexinpatientswithmetastaticnsclctreatedbyimmunotherapy |